Verdiva Bio
London, England, United Kingdom · Biopharma, Biotechnology, Health Care
Verdiva Bio is committed to developing next-generation therapies to help people living with obesity, cardiometabolic disorders, and related complications achieve better outcomes via more patient-friendly therapeutic options. Verdiva’s most advanced therapy is VRB-101, an oral GLP-1 peptide in clinical development that has demonstrated best-in-class efficacy potential in a phase 1 study in Australi
Key facts
- Headquarters
- London, England, United Kingdom
- Employees
- 11
- Industries
- Biopharma, Biotechnology, Health Care
- Status
- Private
- Website
- verdivabio.com
- Company page
Recent activity at Verdiva Bio
- : Verdiva Bio Appoints Steve Marso as Chief Medical Officer
- : Verdiva Bio Appoints New Chief Medical Officer
- : Verdiva Bio launches as a clinical-stage biopharmaceutical company focused on treating obesity and cardiometabolic disorders with over $410M in Series A financing.
- : Verdiva Bio Limited raised $411M in a Series A funding led by Forbion and General Atlantic to develop innovative therapies for obesity and cardiometabolic disorders.
Verdiva Bio funding history
| Date | Round | Amount |
|---|---|---|
| Jan 2025 | Series A | $411.0M |
Leadership
- Steve Marso, Chief Medical Officer
- New Chief Medical Officer, Chief Medical Officer
- Jane Hughes, Founder
- Khurem Farooq, Founder
Verified email and direct lines for Verdiva Bio’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Verdiva Bio in the news
- Verdiva Bio, a New Clinical-Stage Cardiometabolic Company, Launches with Over $410M in Series A Financing to Advance Next-Generation Therapies - General Atlantic (Jan 09, 2025)
- Verdiva Bio Appoints Cardiometabolic Leader Steve Marso as Chief Medical Officer - BioSpace (Jul 23, 2026)
- Verdiva Bio Announces Completion of Enrollment for EVOLVE-2 Phase 2b Study of VRB-101, a Potential Once-Weekly Oral GLP-1 Peptide Analog in Individuals with Obesity - Business Wire (Feb 24, 2026)
- Verdiva Bio Initiates Phase 1 Study of VRB-103, a Selective Oral Amylin Peptide Analog With Weekly Dosing Potential - BioSpace (Jul 30, 2026)
- Verdiva Bio to Present Preclinical Data on Investigational Obesity Drug Candidates at the American Diabetes Association 86th Scientific Sessions - Business Wire (May 20, 2026)
Companies similar to Verdiva Bio
- Ensho Therapeutics · Biopharma, Biotechnology, Health Care, Pharmaceutical, Therapeutics
- Lighthouse Pharmaceuticals · Biopharma, Biotechnology, Health Care, Pharmaceutical, Therapeutics
- Tarsier Pharma · Biopharma, Biotechnology, Health Care, Pharmaceutical, Therapeutics
- Sorriso Pharmaceuticals · Biopharma, Biotechnology, Health Care, Pharmaceutical, Therapeutics
- Jubilant Therapeutics · Biopharma, Biotechnology, Health Care, Pharmaceutical, Therapeutics
About Verdiva Bio: questions and answers
What does Verdiva Bio do?
Verdiva Bio is committed to developing next-generation therapies to help people living with obesity, cardiometabolic disorders, and related complications achieve better outcomes via more patient-friendly therapeutic options. Verdiva’s most advanced therapy is VRB-101, an oral GLP-1 peptide in clinical development that has demonstrated best-in-class efficacy potential in a phase 1 study in Australi
Where is Verdiva Bio headquartered?
Verdiva Bio is headquartered in London, England, United Kingdom.
How many employees does Verdiva Bio have?
Verdiva Bio has about 11 employees.
Has Verdiva Bio raised funding?
Yes. Fundz has recorded 1 funding event for Verdiva Bio. The most recent, Series A of $411.0M, was in Jan 2025.
Who leads Verdiva Bio?
Jane Hughes is a Founder at Verdiva Bio.
What is the latest news on Verdiva Bio?
On Jul 23, 2026, Verdiva Bio Appoints Steve Marso as Chief Medical Officer
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy